Thus, the use of JAK2 inhibitors for β-thalassemia might be desirable, but it would require careful optimization, noting the potential for off-target immune suppression, as well as the anemia that would be expected from continuous JAK2 inhibition. This evidence concerns the gene JAK2 and anemia (phenotype).